期刊文献+

转基因完全人抗体的制备及其抗肿瘤作用研究 被引量:2

Research on the preparation of transgenic fully human antibody and its anti-tumor effects
下载PDF
导出
摘要 肿瘤导向治疗中,由于所用鼠源性抗体的分子量大、免疫原性强、半衰期长及反复应用易产生人抗鼠抗体(human anti-murine antibody, HAMA)反应等弊端,使其在临床的应用受到很大限制.而采用基因工程技术改造的大部分小分子人源化抗体,由于亲和力较弱、产量低、制备费时和纯化费用高等原因,难以在临床上取得较好的疗效.1994年,美国Abgenix和Genpham两公司报告了利用转基因小鼠制备完全人抗体,从而解决了人体不能被随意免疫这一人抗体制备研究的难题.此后完全人抗体制备技术的不断发展成熟,所获人单克隆抗体(mAb)已具有较强的抗肿瘤活性.
出处 《中华神经外科疾病研究杂志》 CAS 2002年第1期90-91,共2页 Chinese Journal of Neurosurgical Disease Research
  • 相关文献

参考文献16

  • 1Sherman-Gold R. Monoclonal antibodies: the evolution from 80's magic bullets to mature, mainstream applications as clinical therapeutics [N]. Genetic Engineering News, 1997, 17: 460-463.
  • 2Lonberg N, Taylor LD, Harding FA, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications [J]. Nature, 1994, 368: 856-859.
  • 3Mendez MJ, Green LL, Corvalan JFR, et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice [J]. Nat Genet, 1997, 15: 146-156.
  • 4Lewin DI. New xenomice make wide array of human antibodies [J]. NIH Res, 1997, 9: 31-32.
  • 5Green LL, Jakobovits A. Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes [J]. J Exp Med, 1998, 188: 483-495.
  • 6Green LL, Hardy MC, Maynard-Currie CE, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs [J]. Nat Genet, 1994, 7: 13-21.
  • 7Fishwild DM, O'Donnell SL, Bengoechea T, et al. High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice [J]. Nat Biotechnol, 1996, 14: 845-851.
  • 8Cobleigh MA, Bogel CL, Tripathy D, et al. Efficacy and safety of humanized anti-HER2 antibody as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer [J]. Proc Am Soc Clin Oncol, 1998, 17: 97-102.
  • 9Viloria PAM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors [J]. Am J Pathol, 1997, 151: 1523-1530.
  • 10Yang XD, Jia XC, Corvalan JRF, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy [J]. Cancer Res, 1999, 59: 1236-1243.

同被引文献48

  • 1张阳德,李浩,李玉坤,龚连生,黄秋,林孙颖,席浩.半乳糖化白蛋白磁性阿霉素纳米粒体外杀伤肝癌细胞的实验研究[J].中华实验外科杂志,2004,21(9):1067-1069. 被引量:10
  • 2连彦军,陈道达,许天文,郑勇斌,黄韬,柯茂林.抗-CEA单抗-β-葡萄糖苷酶偶联物特异性激活苦杏仁苷对LoVo细胞的细胞毒作用研究[J].中国普外基础与临床杂志,2005,12(2):138-141. 被引量:12
  • 3Feodorova V A,Devdariani Z L.Development,characterisation and diagnostic application of monoclonal antibodies against Yersinia pestis fibrinolysin and coagulase[J].J Med Microbiol,2000,49:261-269.
  • 4Hainsworth J D.Monoclonal antibody therapy in lymphoid malignancies[J].Oncologist,2000,5:376-384.
  • 5Dickman S.Antibodies stage a comeback in cancer treatment[J].Science,1998,280:1196-1197.
  • 6Weiner L M.An overview of monoclonal antibody therapy of cancer[J].Sem in Oncol,1999,26:41-50.
  • 7Niculescu-Duvaz I.Technology evaluation:gemtuzumab ozogamicin,celltech group[J].Curr Opin Mol Ther,2000(2):691-696.
  • 8Guang Xu,Howard L M.Strategies for enzyme/prodrug cancer therapy[J].Clinical Cancer Research,2001(7):3314-3324.
  • 9Napier M P,Sharma S K.Antibody-directed enzyme prodrug therapy:efficacy and mechanism of action in colorectal carcinomal[J].Clinical Cancer Research,2000(6):765-772.
  • 10Vrouenraets M B,Gerard W M.Targeting of Aluminum (Ⅲ) phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies:improved efficacy in photodynamic therapy[J].Cancer Research,2001,61(5):1970-1975.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部